Back

Comments on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose

European Heart Journal - Cardiovascular Pharmacotherapy

2 April 2020
Organised by: Logo
Read full article
ESC Journals

Contributors

Jutta Heinrich-Nols
Jutta Heinrich-Nols

Author

Joanne van Ryn
Joanne van Ryn

Author

You may be interested in
thumbnail
Congress Presentation
Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries
1 September 2019
thumbnail
Congress Presentation
Comparative analysis of therapeutic strategies in atrial fibrillation patients with left atrial appendage thrombus despite optimal NOAC therapy
1 September 2025
thumbnail
Webinar
Anticoagulation challenges in older subjects with multimorbidity
25 July 2023
thumbnail
Congress Presentation
Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
31 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources